Latest News

Added 23 hours ago Drug news

FDA approves Tibsovo to treat AML with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation.- Agios Pharma.

Agios Pharmaceuticals, Inc. has announced that Tibsovo (ivosidenib) was granted approval from the FDA for the treatment of adult patients...

Added 23 hours ago Drug news

FDA approval of Tibsovo to treat AML is based on Study AG120-C-001, NCT02074839.- Agios Pharma.

The FDA approval for Tibsovo (ivosidenib) was based on the clinical data from an open-label, single-arm, multicenter dose-escalation and expansion...

Added 23 hours ago Drug news

Successful Phase III study of Vyxeos compared to standard of care for AML is published in the Journal of Clinical Oncology.

Jazz Pharmaceuticals plc announced that data from the pivotal Phase III study of Vyxeos (daunorubicin and cytarabine) liposome for injection...

 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Communicating Metastatic Breast Cancer Learning Zone

Communicating Metastatic Breast Cancer Learning Zone

This learning zone offers a short overview of the challenges faced by both healthcare professionals and patient when communicating end-stage or metastatic cancer.

Breakthrough Cancer Pain Learning Zone

Breakthrough Cancer Pain Learning Zone

Watch video highlights from the BeCOn OWN 2017 event, including expert opinion, patient experience and panel discussions in the Breakthrough Cancer Pain Learning Zone.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more

What's on the horizon?

Marshall Pearce

Antibody-drug conjugates (ADCs)

Posted 1 year ago

Over the past couple of decades, there have been advances in a class of drugs which for a long time was purely theoretical: antibody-drug conjugates (ADCs). The concept underlying ADCs is elegant – what if it were possible to ‘target’ particular groups of cells with a cytotoxic agent, rather than exposing every cell of the body to it?

Marshall Pearce

Cancer immunotherapies

Posted 1 year ago

It was the winner of the 1908 Nobel prize for medicine, Paul Ehrlich, who is first credited with discussing the concept of a “magic bullet”, able to target specific cells without damaging healthy tissue. With the advent of immunotherapy, as well as antibody-drug conjugates, we are beginning to realise this vision.

Guidelines

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.

Added 1 month ago

Guidelines on Penile Cancer

The European Association of Urology (EAU) Guidelines on Penile Cancer provides up-to-date information on the diagnosis and management of penile squamous cell carcinoma (SCC).

Added 4 years ago

Guidelines on Primary Urethral Carcinoma

The European Association of Urology (EAU) Guidelines Group on Muscle-invasive and Metastatic Bladder Cancer has prepared these guidelines to deliver current evidence-based information on the diagnosis and treatment of patients with...

Added 3 years ago

Search all guidelines for Oncology
 

Journal articles

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

The aim of this study was to assess the efficacy and safety of a lower dose of dasatinib (50 mg daily) in patients with newly diagnosed CML-CP.

Added 2 days ago

Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer.

Atezolizumab is approved as monotherapy in several countries worldwide for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have previously received chemotherapy.

Added 2 days ago

Impact of siltuximab on patient-related outcomes in multicentric Castleman's disease.

Siltuximab is an anti-IL-6 chimeric monoclonal antibody that acts as a novel treatment modality to bind to IL-6 with high affinity, thus neutralizing the cytokine bioactivity and inhibiting B-cell proliferation.

Added 2 days ago

Search all journal articles for Oncology
 

Clinical trials

Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma

The goal of this clinical research study is to compare the safety and effectiveness of cabozantinib and sunitinib when given to patients with metastatic (has spread) variant histology renal cell carcinoma (vhRCC), a type of kidney cancer.

Added 4 days ago

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer (EarLEE-2)

This is an international, multi-center, randomized, double-blinded, placebo-controlled clinical study evaluating the efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive...

Added 8 months ago

COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation (COLLISION)

The primary objective is to prove non-inferiority of thermal ablation compared to hepatic resection in patients with at least one resectable and ablatable colorectal liver metastases (≤3cm) and no extrahepatic disease.

Added 8 months ago

Search all clinical trials for Oncology
 

Blog Posts

Allen Wellings

ELCC 2018 ‒ Roundup of this year’s conference

Posted 3 months ago

At the recent ELCC, held from 11‒14 April 2018, several hundred abstracts were presented detailing the latest cutting-edge research in lung cancer treatment and care. Brief summaries of some of the key abstracts are found here.

Alex Keen

ELCC 2018 ‒ And the Heine H. Hansen Award goes to…

Posted 3 months ago

Discover this year's Heine H. Hansen award winner, given to a scientific investigator who has made special, wide-reaching and significant contributions to lung cancer research and education, recognising their lifelong achievements.

Allen Wellings

EBCC 2018 – Roundup of this year's conference

Posted 3 months ago

At the recent European Breast Cancer Conference the best and brightest in breast cancer research and care met to present and discuss the latest breakthroughs. Brief summaries of some of the key abstracts are found here.

CME

Treatment Optimisation in Chronic Lymphocytic Leukaemia

Treatment Optimisation in Chronic Lymphocytic Leukaemia
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE

Managing the side effects of treatment for prostate cancer

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90

Managing patients at risk of prostate cancer

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90
Search all CME for Oncology